arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

NEUROONE MEDICAL TECHNOLOGIES Corp

NMTC
$1.58 ▲ +0.04 (+2.92%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
65 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

NEUROONE MEDICAL TECHNOLOGIES Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $13.4M
Dividend Yield
Revenue Growth 72.5%
Op. Margin -87.9%
ROIC -30.9%
FCF / Share $-0.16
Trailing P/E
Price / Book 2.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.39M
↑ +72.5%
Net Income Profit after all expenses
$-1.44M
— 0.0%
Operating Margin Operating profit as % of sales
-87.9%
↓ -48.9% 5th
FCF / Share Free cash flow per share
$-0.16
↓ -156.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
16
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 65 quarters